Acquired Companies

At Mallinckrodt Pharmaceuticals, we continually look for companies and products that align with our strategic vision – to be an innovation-driven specialty pharmaceutical company focused on improving outcomes for patients with severe and critical conditions. Our acquisitions help enhance and expand our diverse product portfolio and growing pipeline. To see information related to some of the companies we have acquired along the way, select from the growing list below.


InfaCare Pharmaceutical Corporation

On September 25, 2017, Mallinckrodt announced the completion of its acquisition of InfaCare Pharmaceutical Corporation, a privately held specialty pharmaceutical company focused on development and commercialization of proprietary pharmaceuticals for neonatal and pediatric patient populations. Mallinckrodt made an upfront payment of $80 million, with additional payments of up to $345 million to be paid depending on achievement of certain regulatory and sales milestones.

Former InfaCare shareholders looking for more information should contact the InfaCare Shareholders Representative, Karen Lok, who can be reached at shrep@longitudecapital.com. To request a new or replacement copy of your Letter of Transmittal to submit your shares for payment, please contact Citibank, the paying agent for this transaction, at 1-877-498-5424 (U.S. and Canada) or 1-781-633-4175 (outside of U.S. and Canada).


Sucampo Pharmaceuticals, Inc.

SEC Filings
Filing date Form Description Filing Group Downloads
15-12B

Termination of registration under Section 12(g) or suspension of duty to file reports

Other
SC 13D/A

An amendment to a SC 13D filing

Other
SC 13D/A

An amendment to a SC 13D filing

Other
EFFECT

EFFECT

Other
EFFECT

EFFECT

Other
EFFECT

EFFECT

Other
EFFECT

EFFECT

Other
4

Statement of changes in beneficial ownership of securities

3,4,5
4

Statement of changes in beneficial ownership of securities

3,4,5
25-NSE

25-NSE

Other

Cadence Pharmaceuticals

(Acquired by Mallinckrodt Pharmaceuticals in 2014)
2012
Title
2011
Title
Filing date Form Description Filing Group Downloads
CT ORDER

CT ORDER

Other
15-12B

Termination of registration under Section 12(g) or suspension of duty to file reports

Other
SC 13D/A

An amendment to a SC 13D filing

Other
4

Statement of changes in beneficial ownership of securities

3,4,5
4

Statement of changes in beneficial ownership of securities

3,4,5
4

Statement of changes in beneficial ownership of securities

3,4,5
4

Statement of changes in beneficial ownership of securities

3,4,5
4

Statement of changes in beneficial ownership of securities

3,4,5
4

Statement of changes in beneficial ownership of securities

3,4,5
4

Statement of changes in beneficial ownership of securities

3,4,5
DateTitle 
02/28/14
SAN DIEGO, Feb. 28, 2014 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, today reported financial results for the three and
Printer Friendly Version
02/11/14
February 11, 2014 Transaction accelerates growth in Mallinckrodt's Specialty Pharmaceuticals segment with addition of a high-growth, differentiated pain product Acquisition supports Mallinckrodt's expansion into the hospital channel Acquisition expected to be immediately accretive to Mallinckrodt's
Printer Friendly Version
01/13/14
SAN DIEGO, Jan. 13, 2014 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, today announced preliminary (unaudited) estimates
Printer Friendly Version
12/09/13
Presentations examine role of OFIRMEV® (acetaminophen) injection in improving outcomes and cost of care for treating acute pain associated with common joint replacement procedures ORLANDO, Fla., Dec. 9, 2013 /PRNewswire/ -- Cadence Pharmaceuticals, Inc.
Printer Friendly Version
11/26/13
SAN DIEGO, Nov. 26, 2013 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, announced today that the company's President and
Printer Friendly Version
11/14/13
SAN DIEGO, Nov. 14, 2013 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, announced today that the U.S.
Printer Friendly Version
11/08/13
Employee feedback through an anonymous survey included strong culture and employee engagement as top reasons to work for the company SAN DIEGO, Nov. 8, 2013 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on acquiring, in-licensing, developing and
Printer Friendly Version
11/05/13
SAN DIEGO, Nov. 5, 2013 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, today reported financial results for the three and
Printer Friendly Version
10/29/13
SAN DIEGO, Oct. 29, 2013 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, today announced that it will release its third
Printer Friendly Version
09/04/13
SAN DIEGO, Sept. 4, 2013 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, announced today that the company's President and CEO Ted
Printer Friendly Version
08/15/13
SAN DIEGO, Aug. 15, 2013 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, announced today the appointment of Laureen DeBuono
Printer Friendly Version
08/15/13
SAN DIEGO, Aug. 15, 2013 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX) today announced that the United States Patent and Trademark Office (USPTO), has issued a non-final, initial office action in the Ex Parte Reexamination of US Patent No.
Printer Friendly Version
08/06/13
SAN DIEGO, Aug. 6, 2013 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, announced today that the company's Senior Vice President and
Printer Friendly Version
07/31/13
SAN DIEGO, July 31, 2013 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, today reported financial results for the three and
Printer Friendly Version
07/24/13
SAN DIEGO, July 24, 2013 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, today announced that it will release its second
Printer Friendly Version
07/02/13
SAN DIEGO, July 2, 2013 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, announced today that the company's President and CEO Ted
Printer Friendly Version
05/08/13
SAN DIEGO, May 8, 2013 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, announced today that the company's management will present a
Printer Friendly Version
05/02/13
SAN DIEGO, May 2, 2013 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, today reported financial results for the first
Printer Friendly Version
04/25/13
SAN DIEGO, April 25, 2013 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, today announced that it will release its first
Printer Friendly Version
03/14/13
SAN DIEGO, March 14, 2013 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, announced today the appointment of Stephen L.
Printer Friendly Version
03/12/13
SAN DIEGO, March 12, 2013 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), announced today that the Department of Veterans Affairs has made OFIRMEV ® (acetaminophen) injection available on the VA National Formulary (VANF). The VANF is a list of products (drugs and supplies) generally
Printer Friendly Version
03/07/13
-- 2012 Net Product Revenue Exceeds $50 Million -- SAN DIEGO, March 7, 2013 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting,
Printer Friendly Version
03/06/13
SAN DIEGO, March 6, 2013 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, today announced a new supply agreement with
Printer Friendly Version
02/28/13
SAN DIEGO, Feb. 28, 2013 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, today announced that it will release its fourth
Printer Friendly Version
02/26/13
SAN DIEGO, Feb. 26, 2013 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, announced today that the company's President and
Printer Friendly Version
02/06/13
SAN DIEGO, Feb. 6, 2013 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, announced today that the company's President and CEO
Printer Friendly Version
01/23/13
SAN DIEGO, Jan. 23, 2013 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, today announced a preliminary (unaudited) estimate
Printer Friendly Version
12/12/12
SAN DIEGO, Calif., Dec. 12, 2012 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, announced today that it has entered into an
Printer Friendly Version

Questcor Pharmaceuticals

(Acquired by Mallinckrodt Pharmaceuticals in 2014)

Title
Filing date Form Description Filing Group Downloads
15-12B

Termination of registration under Section 12(g) or suspension of duty to file reports

Other
8-K

Report of unscheduled material events or corporate event

Current Reports
4

Statement of changes in beneficial ownership of securities

3,4,5
4

Statement of changes in beneficial ownership of securities

3,4,5
4

Statement of changes in beneficial ownership of securities

3,4,5
4

Statement of changes in beneficial ownership of securities

3,4,5
4

Statement of changes in beneficial ownership of securities

3,4,5
4

Statement of changes in beneficial ownership of securities

3,4,5
4

Statement of changes in beneficial ownership of securities

3,4,5
4

Statement of changes in beneficial ownership of securities

3,4,5
DateTitle 
08/04/14
DUBLIN and ANAHEIM, Calif., Aug. 4, 2014 /PRNewswire/ --  Mallinckrodt plc  (NYSE: MNK) (" Mallinckrodt ") and  Questcor Pharmaceuticals, Inc.  (NASDAQ: QCOR) ("Questcor") today jointly announced that two leading independent proxy advisory firms, Institutional Shareholder Services Inc.
Printer Friendly Version
07/24/14
Net Sales $279 Million; Increase of 42% over Prior Year Non-GAAP Results GAAP EPS of $1.54, Non-GAAP EPS of $1.85 up 37% Year-Over-Year $99 Million of Operating Cash Flow Record 8,850 Acthar Vials Shipped in Quarter, up 26% over Prior Year Launched Commercial Effort in Lupus Expanding Pulmonology
Printer Friendly Version
07/14/14
--Registration Statement on Form S-4 Declared Effective by SEC-- --Record Dates for Mallinckrodt and Questcor Set for July 9, 2014-- --Companies Schedule Shareholder Meetings for August 14, 2014-- --Transaction Expected to be Completed in August 2014-- DUBLIN, IRELAND and ANAHEIM, CALIFORNIA - July
Printer Friendly Version
06/23/14
- Initiates Global Footprint, Diversifies Business, Enhances Long-term Growth Prospects - /* Style Definitions */ span.prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.prnews_a { color:blue; } li.prnews_li { font-size:8pt; font-family:"Arial"; color:black; } p.prnews_p {
Printer Friendly Version
06/03/14
Company sponsors Walk to End Lupus Now™ events and employees show support for people with the disease during Lupus Awareness Month /* Style Definitions */ span.prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.prnews_a { color:blue; } li.prnews_li { font-size:8pt;
Printer Friendly Version
05/28/14
HAYWARD, Calif., May 28, 2014 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today announced that it has been honored with a "Recognition of Appreciation" Award from MS Views & News, Inc., a leading multiple sclerosis (MS) education, information and advocacy organization.
Printer Friendly Version
05/14/14
- Expands pipeline and broadens platform with next-generation melanocortin peptides - - Further enhances leadership position in melanocortin therapeutics - /* Style Definitions */ span.prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.prnews_a { color:blue; } li.prnews_li {
Printer Friendly Version
05/12/14
May 12, 2014 DUBLIN, Ireland & ANAHEIM, Calif.--(BUSINESS WIRE)-- Mallinckrodt plc ( MNK ), and Questcor Pharmaceuticals, Inc. ( QCOR ), today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), in connection with Mallinckrodt's
Printer Friendly Version
05/05/14
- Significant clinical response to Acthar was observed in patients experiencing active disease while on conventional SLE maintenance therapies - - Findings supported by recent preclinical data demonstrating potential immunomodulatory activity and efficacy of Acthar in a mouse model of SLE - /*
Printer Friendly Version
04/28/14
- Net Sales $227 Million; Increase 68% Year-over-Year - - GAAP EPS of $1.20, Non-GAAP EPS of $1.40 up 84% - - $106M of Operating Cash Flow - - Rheumatology Largest Growth Contributor - - Mallinckrodt / Questcor Joint Merger Proxy Expected to be Filed in Mid-May - ANAHEIM, Calif., April 28, 2014
Printer Friendly Version
04/24/14
ANAHEIM, Calif., April 24, 2014 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) today announced that it will release first quarter 2014 financial results on Monday, April 28, 2014 after the close of the U.S. financial markets. In light of Questcor's pending merger with Mallinckrodt
Printer Friendly Version
04/21/14
- Clinical results appear to correlate with reduction in anti-PLA2R antibodies /* Style Definitions */ span.prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.prnews_a { color:blue; } li.prnews_li { font-size:8pt; font-family:"Arial"; color:black; } p.prnews_p { font-size:0.62em;
Printer Friendly Version
04/17/14
HAYWARD, Calif., April 17, 2014 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today announced that it is partnering with the National Kidney Foundation (NKF) to become a National Sponsor of Kidney Walk, the country's largest walk to raise money and awareness for kidney disease.
Printer Friendly Version
04/07/14
--Questcor Shareholders Receive $30.00 in Cash and 0.897 Mallinckrodt Shares for Each Share of Questcor Common Stock They Own-- --Combined Company Expected to Have Significantly Increased Scale, Revenues, Profitability and Cash Flow to Deliver Sustainable Growth Built on a More Diversified Product
Printer Friendly Version
04/07/14
ANAHEIM, Calif., April 7, 2014 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) today announced that its Board of Directors has declared a quarterly cash dividend of $0.30 per share ($1.20 per share on an annual basis). The dividend will be paid on or about July 8, 2014 to shareholders
Printer Friendly Version
03/20/14
- Company's total commitment to Endowment reaches $250,000 - /* Style Definitions */ span.prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.prnews_a { color:blue; } li.prnews_li { font-size:8pt; font-family:"Arial"; color:black; } p.prnews_p { font-size:0.62em; font-family:"Arial";
Printer Friendly Version
02/25/14
- Fourth Quarter Net Sales $243 Million; Increase 51% Year-over-Year - - Fourth Quarter GAAP EPS of $1.44, Non-GAAP EPS of $1.67 up 53% - - Full Year 2013 Net Sales $799 Million; Increase 57% Year-over-Year - - Full Year GAAP EPS of $4.76, Non-GAAP EPS of $5.48 up 65% - - Rheumatology Largest
Printer Friendly Version
02/14/14
ANAHEIM, Calif., Feb. 14, 2014 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) today announced that its Board of Directors has declared a quarterly cash dividend of $0.30 per share ($1.20 per share on an annual basis). The dividend will be paid on or about April 25, 2014 to
Printer Friendly Version
02/12/14
ANAHEIM, Calif., Feb. 12, 2014 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) today announced that it will release fourth quarter and full year 2013 financial results on Tuesday, February 25, 2014 after the close of the U.S. financial markets.
Printer Friendly Version
02/05/14
ANAHEIM, Calif., Feb. 5, 2014 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today announced the appointment of Rajesh (Raj) Asarpota as the Company's new Chief Financial Officer, effective February 17, 2014. Michael H. Mulroy, the Company's current CFO, will become Executive Vice
Printer Friendly Version
01/22/14
- Ten researchers awarded fellowship grants to further study in neurology, nephrology and rheumatology - HAYWARD, Calif., Jan. 22, 2014 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today announced that it has funded independent researchers at 10 institutions for 2014.
Printer Friendly Version
01/08/14
ANAHEIM, Calif., Jan. 8, 2014 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) announced today that Don Bailey, the Company's President and Chief Executive Officer, will present at the J.P. Morgan Healthcare Conference in San Francisco on January 16, 2014 at 9:00 AM PT/12:00 PM ET.
Printer Friendly Version
12/17/13
HAYWARD, Calif., Dec. 17, 2013 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR ) today announced that it has made a $25,000 donation to the Children's Hospital & Research Center Oakland in support of the Early Intervention Services program.
Printer Friendly Version
12/11/13
ANAHEIM, Calif., Dec. 11, 2013 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) today announced that its Board of Directors has declared a quarterly cash dividend of $0.30 per share ($1.20 per share on an annual basis). The dividend will be paid on or about January 24, 2014 to
Printer Friendly Version
12/09/13
- IS Hero Award goes to Dr. Carolina Amador and the staff at Lincoln Health Center, Corvallis, Oregon /* Style Definitions */ span.prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.prnews_a { color:blue; } li.prnews_li { font-size:8pt; font-family:"Arial"; color:black; } p.prnews_p
Printer Friendly Version
12/05/13
ANAHEIM, Calif., Dec. 5, 2013 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) announced today that executive management will present at the Oppenheimer 24th Annual Healthcare Conference in New York City on December 11, 2013 at 8:20 AM ET/5:20 AM PT.
Printer Friendly Version
11/22/13
-- Company recognized at NephCure annual "Countdown for a Cure" fundraiser /* Style Definitions */ span.prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.prnews_a { color:blue; } li.prnews_li { font-size:8pt; font-family:"Arial"; color:black; } p.prnews_p { font-size:0.62em;
Printer Friendly Version
11/12/13
ANAHEIM, Calif., Nov. 12, 2013 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today announced the addition of G. Kelly Martin, President and Chief Executive Officer of Elan Corporation, plc, to Questcor's Board of Directors, bringing the number of directors to eight, seven of whom
Printer Friendly Version
11/07/13
ANAHEIM, Calif., Nov. 7, 2013 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) announced today that executive management will present at the 2013 Credit Suisse Annual Healthcare Conference in Scottsdale, AZ on November 14, 2013 at 8:00 AM PT/11:00 AM ET.
Printer Friendly Version
10/29/13
- Net Sales and EPS Increase Over 65% Compared to Prior Year - - Vial Shipments up 45% Over Prior Year - - Record MS Prescriptions; Rheumatology Largest Growth Contributor - ANAHEIM, Calif., Oct. 29, 2013 /PRNewswire/ -- Questcor Pharmaceuticals, Inc.
Printer Friendly Version
10/22/13
ANAHEIM, Calif., Oct. 22, 2013 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) announced today that it will commence a Phase 2 study to explore the efficacy and safety of H.P. Acthar® Gel (repository corticotropin injection) for Acute Respiratory Distress Syndrome (ARDS).
Printer Friendly Version
10/10/13
Dividend Increased to $1.20 per Share on an Annual Basis Second Dividend Increase in 2013 Reflects Growing Cash Flow /* Style Definitions */ span.prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.prnews_a { color:blue; } li.prnews_li { font-size:8pt; font-family:"Arial";
Printer Friendly Version
10/08/13
ANAHEIM, Calif., Oct. 8, 2013 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) today announced that it will release third quarter 2013 financial results on Tuesday, October 29, 2013 after the close of the U.S. financial markets. The Company will host a conference call and slide
Printer Friendly Version
09/05/13
ANAHEIM, Calif., Sept. 5, 2013 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) announced today that executive management will host investor meetings and will be a participant in a fireside chat session at the Morgan Stanley Global Healthcare Conference in New York City on September
Printer Friendly Version
08/27/13
ANAHEIM, Calif., Aug. 27, 2013 /PRNewswire/ --Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) announced today that executive management will present at the Morgan Stanley Global Healthcare Conference in New York City on September 10, 2013 at 4:40 PM ET/1:40 PM PT.
Printer Friendly Version
07/30/13
- Net Sales and EPS Increase Significantly Over Prior Year - - Vial Shipments up 50% Over Prior Year - - Total Shipped Rxs up 35% YOY; Rheumatology Rxs Largest Growth Contributor - ANAHEIM, Calif., July 30, 2013 /PRNewswire/ -- Questcor Pharmaceuticals, Inc.
Printer Friendly Version
07/24/13
ANAHEIM, Calif., July 24, 2013 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) announced today that patient screening will commence in connection with Questcor's Phase 2 Study to explore the safety and tolerability of H.P. Acthar® Gel (repository corticotropin injection) in patients
Printer Friendly Version
07/12/13
ANAHEIM, Calif., July 12, 2013 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) today announced that it will release second quarter 2013 financial results on Tuesday, July 30, 2013 after the close of the U.S. financial markets. The Company will host a conference call and slide
Printer Friendly Version
07/11/13
ANAHEIM, Calif., July 11, 2013 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today announced its intent to initiate a pilot commercialization effort for H.P. Acthar® Gel (repository corticotropin injection) for the treatment of respiratory manifestations of symptomatic sarcoidosis,
Printer Friendly Version
06/11/13
- Expands Questcor's Presence in Inflammatory and Autoimmune Disorders - - Provides Foundation for Next Generation Melanocortin Receptor Agonist Therapeutics - - Initiates Global Footprint, Diversifies Business, Enhances Long-term Growth Prospects - /* Style Definitions */ span.prnews_span {
Printer Friendly Version
06/10/13
ANAHEIM, Calif., June 10, 2013 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today announced the addition of Angus C. Russell, recently-retired Chief Executive Officer of Shire plc, to Questcor's Board of Directors. Shire is a global specialty biopharmaceutical company whose 2012
Printer Friendly Version
05/29/13
ANAHEIM, Calif., May 29, 2013 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) announced today that its Board of Directors has declared a quarterly cash dividend of $0.25 per share to shareholders of record at the close of business on July 22, 2013.
Printer Friendly Version
05/08/13
ANAHEIM, Calif., May 8, 2013 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) announced today that executive management will present at the Bank of America Merrill Lynch 2013 Healthcare Conference in Las Vegas on May 14, 2013 at 4:20 PM PT/7:20 PM ET.
Printer Friendly Version
04/30/13
- Net Sales Increase 41% Year Over Year; Down Sequentially - - April Vial Shipments Rebound Significantly Establishing a New Monthly Record- - Prescription Levels in Rheumatology Increasing - - Phase 2 Clinical Trial of Acthar in ALS to Start under FDA Accepted IND - ANAHEIM, Calif., April 30, 2013
Printer Friendly Version
04/15/13
ANAHEIM, Calif., April 15, 2013 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today announced that it will release first quarter 2013 financial results on Tuesday, April 30, 2013 after the close of the U.S. financial markets. The Company will host a conference call and slide
Printer Friendly Version
02/26/13
- Net Sales, EPS and Cash Flow from Operations Increase Significantly Over Prior Year Period - - Continues to Expand R&D Efforts - - Increases Quarterly Dividend 25% to $0.25 per share - ANAHEIM, Calif., Feb. 26, 2013 /PRNewswire/ -- Questcor Pharmaceuticals, Inc.
Printer Friendly Version
02/06/13
ANAHEIM, Calif., Feb. 6, 2013 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today announced that it will release fourth quarter and full year 2012 financial results on Tuesday, February 26, 2013 after the close of the U.S. financial markets.
Printer Friendly Version
01/28/13
ANAHEIM, Calif., Jan. 28, 2013 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today announced the appointment of Michael Aldridge to the new position of Senior Vice President, Corporate Strategic Development. Mr. Aldridge's primary responsibilities will be the identification and
Printer Friendly Version
01/03/13
ANAHEIM, Calif., Jan. 3, 2013 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) announced today that executive management is scheduled to present at the 31st Annual J.P. Morgan Healthcare Conference in San Francisco, California, on Thursday, January 10, 2013 at 9:00 a.m. PT / 12:00 p.m.
Printer Friendly Version
01/02/13
-- Transaction provides vertical integration, third party manufacturing capabilities and further secures Acthar manufacturing trade secrets -- -- Acquisition expected to be accretive to future financial results -- /* Style Definitions */ span.prnews_span { font-size:8pt; font-family:"Arial";
Printer Friendly Version
12/04/12
ANAHEIM, Calif., Dec. 4, 2012 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ:QCOR) today announced that its Board of Directors has declared a quarterly cash dividend of $0.20 per share to all shareholders of record at the close of business on December 14, 2012.
Printer Friendly Version
12/03/12
- CNF Names Dr. Alex R. Paciorkowski of the University of Rochester Medical Center as 2012 Recipient of CNF's Infantile Spasms Research Award /* Style Definitions */ span.prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.prnews_a { color:blue; } li.prnews_li { font-size:8pt;
Printer Friendly Version